Shilpa Medicare Ltd

Shilpa Medicare announced that the Board of Directors of the Company at its meeting held on 22 May 2026, inter alia, have recommended the final dividend of Rs 0.6 per equity Share (i.e. 60%) , subject to the approval of the shareholders.

Net profit of Shilpa Medicare rose 642.87% to Rs 107.79 crore in the quarter ended March 2026 as against Rs 14.51 crore during the previous quarter ended March 2025. Sales rose 32.09% to Rs 436.99 crore in the quarter ended March 2026 as against Rs 330.82 crore during the previous quarter ended March 2025. For the full year,net profit rose 210.81% to Rs 243.33 crore in the year ended March 2026 as against Rs 78.29 crore during the previous year ended March 2025. Sales rose 19.62% to Rs 1538.87 crore in the year ended March 2026 as against Rs 1286.43 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales436.99330.82 32 1538.871286.43 20 OPM %27.3923.94 -28.2524.73 - PBDT126.0474.65 69 402.87265.90 52 PBT95.4245.86 108 283.15152.91 85 NP107.7914.51 643 243.3378.29 211 Powered by Capital Market - Live

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 22 May 2026.

Shilpa Medicare has appointed Dr. Vellaian Karuppiah has been appointed as the Chief Operating Officer (COO) - Formulations (Senior Managerial Personnel) of the Company with effect from 23 April 2026.

SteinCares is a leading specialty pharmaceutical company dedicated to expanding patient access to innovative and cost-effective treatments across Latin America. Shilpa Biologicals is a fully integrated biopharmaceutical company with a therapeutic focus on immunology, oncology, and ophthalmics. As a hybrid CDMO/pharma company, Shilpa offers both development and manufacturing services alongside ready-to-license novel formulations. Under the agreement, SteinCares will hold exclusive rights to register, commercialize, and distribute the biosimilar across the region while Shilpa Biologicals will complete product development and provide long-term commercial manufacturing from its facility in Dharwad, India. The partnership brings together Shilpa Biologicals' expertise in biologics development and high-quality commercial manufacturing with SteinCares' integrated regional platform, combining regulatory capabilities, market access, and deep understanding of Latin American healthcare systems. Shilpa Medicare is a manufacturer of API, formulation, and development services. The company's consolidated net profit jumped 40.28% to Rs 44.58 crore on a 28.32% increase in revenue to Rs 409.73 crore in Q3 FY26 as compared with Q3 FY25. The scrip fell 1.33% to currently trade at Rs 322.95 on the BSE. Powered by Capital Market - Live

SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals, a fully integrated biopharmaceutical company and subsidiary of Shilpa Medicare, announce a strategic licensing agreement to commercialize a biosimilar across Latin America. Under the agreement, SteinCares will hold exclusive rights to register, commercialize, and distribute the biosimilar across the region while Shilpa Biologicals will complete product development and provide long-term commercial manufacturing from its facility in Dharwad, India. The partnership brings together Shilpa Biologicals' expertise in biologics development and high quality commercial manufacturing with SteinCares' integrated regional platform, combining regulatory capabilities, market access, and deep understanding of Latin American healthcare systems. Powered by Capital Market - Live

Shilpa Medicare (SML) has entered into a binding agreement with NXI Therapeutics AG based out of Basel, Switzerland for development, supply of a New Chemical Entity (NCE). Under the terms of the strategic collaboration, SML will support both development - including first-in-human clinical studies - as well as long-term commercial supply with GMP manufacturing. Powered by Capital Market - Live

Shilpa Medicare has filed its Rotigotine 1, 2, 3, 4, 6, 8 mg/24 h transdermal patch USP, ANDA for US market, marking its first-ever transdermal patch submission to the U.S. Food and Drug Administration (USFDA). This application submitted as an ANDA with USFDA is a generic version of the innovator product Neupro'. Shilpa' s product is pharmaceutical and bioequivalent version of the reference product Neupro'. Shilpa' s Rotigotine patches are indicated for treatment of Restless Legs Syndrome and Parkinson's disease. The total addressable US market for Rotigotine is estimated at USD 112 million. This Filling represents a significant milestone for the Company, being Shilpa Medicare's First transdermal patch dosage form, which is a complex dosage form to be filed in the US market. The once-daily, patient friendly transdermal formulation ensures reproducible, sustained, and controlled release of medication, enhancing patient compliance. This submission has come from the Company's finished dosage form manufacturing facility, Shilpa Medicare Ltd, Unit VI, located at Dobbaspet, Bengaluru, Karnataka. The facility is involved in manufacturing, packaging, labelling and testing of specialized finished dosage forms as oral dispersible/dissolving Films and Transdermal Patches. Powered by Capital Market - Live

Net profit of Shilpa Medicare rose 40.28% to Rs 44.58 crore in the quarter ended December 2025 as against Rs 31.78 crore during the previous quarter ended December 2024. Sales rose 28.32% to Rs 409.73 crore in the quarter ended December 2025 as against Rs 319.30 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales409.73319.30 28 OPM %27.8125.26 - PBDT104.0870.42 48 PBT73.7141.61 77 NP44.5831.78 40 Powered by Capital Market - Live

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 6 February 2026.Powered by Capital Market - Live